Kestra Medical Technologies (NASDAQ:KMTS) Reaches New 1-Year High – Should You Buy?

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) reached a new 52-week high during trading on Wednesday. The stock traded as high as $31.10 and last traded at $30.8840, with a volume of 86,422 shares. The stock had previously closed at $29.01.

Wall Street Analysts Forecast Growth

KMTS has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings raised shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 16th. Royal Bank Of Canada set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Evercore started coverage on Kestra Medical Technologies in a research note on Tuesday, October 20th. They issued an “outperform” rating and a $34.00 price objective on the stock. Finally, JPMorgan Chase & Co. started coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They issued an “overweight” rating and a $30.00 price target on the stock. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.00.

Kestra Medical Technologies Price Performance

The company has a market cap of $1.87 billion, a price-to-earnings ratio of -11.70 and a beta of 0.45. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33. The company has a fifty day simple moving average of $26.79 and a two-hundred day simple moving average of $23.90.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The business had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. On average, equities research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Traci S. Umberger sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $30.03, for a total value of $900,900.00. Following the completion of the transaction, the insider owned 195,825 shares of the company’s stock, valued at $5,880,624.75. The trade was a 13.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Raymond W. Cohen sold 3,330 shares of Kestra Medical Technologies stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $29.28, for a total value of $97,502.40. Following the completion of the sale, the director directly owned 54,790 shares of the company’s stock, valued at approximately $1,604,251.20. This represents a 5.73% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 289,551 shares of company stock valued at $8,171,898. 5.30% of the stock is owned by company insiders.

Institutional Trading of Kestra Medical Technologies

Several institutional investors have recently made changes to their positions in KMTS. Sterling Capital Management LLC grew its position in Kestra Medical Technologies by 834.0% during the third quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock valued at $25,000 after acquiring an additional 784 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kestra Medical Technologies in the 3rd quarter worth about $353,000. Quantinno Capital Management LP acquired a new position in shares of Kestra Medical Technologies in the 1st quarter valued at about $431,000. California State Teachers Retirement System increased its position in Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after purchasing an additional 7,844 shares in the last quarter. Finally, Spartan Wealth Advisory Services LLC acquired a new stake in Kestra Medical Technologies during the 1st quarter worth approximately $603,000.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.